Sage Therapeutics is a biopharmaceutical company focused on developing innovative treatments for central nervous system (CNS) disorders
The company aims to address significant unmet medical needs by leveraging its expertise in neuroscience and advanced drug development. Sage Therapeutics is primarily engaged in the research and development of novel therapeutic compounds designed to target neurological and psychiatric conditions, such as major depressive disorder and epilepsy. Through its commitment to scientific rigor and patient-centered innovation, the company seeks to improve the lives of individuals affected by these challenging disorders.
The small-cap biotech firm called the proposal "significantly undervaluing" the company and added that it was not in the best interest of its shareholders.
Biogen proposes acquiring Sage Therapeutics for $7.22 per share, as analysts highlight the strategic value of Zurzuvae's success in postpartum depression.
Sage Therapeutics announces reorganization, including layoffs and pipeline changes, to support the launch of Zurzuvae. Focus shifts to Huntington's Disease trial after setbacks in essential tremor and Alzheimer's treatments.
Sage Therapeutics' dalzanemdor failed to show significant results in Phase 2 Alzheimer's study. The company discontinues Alzheimer's development but expects Huntington's data soon. Stock drops 10.7%.
Sage Therapeutics announced Biogen's decision to terminate their collaboration on SAGE-324 following negative results from a Phase 2 study, with Sage resuming full ownership of the asset by February 2025.
